UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer

The New England journal of medicine, 2019-07, Vol.381 (4), p.307-316

2019

Volltextzugriff (PDF)

Exploratory Analysis of TP53 Mutations in Circulating Tumour DNA as Biomarkers of Treatment Response for Patients with Relapsed High-Grade Serous Ovarian Carcinoma: A Retrospective Study

PLoS medicine, 2016-12, Vol.13 (12), p.e1002198-e1002198

2016

Volltextzugriff (PDF)

Ribociclib, a CDK 4/6 inhibitor, plus endocrine therapy in Asian women with advanced breast cancer

Cancer science, 2020-09, Vol.111 (9), p.3313-3326

2020

Volltextzugriff (PDF)

Docetaxel and its potential in the treatment of refractory esophagogastric adenocarcinoma

Therapeutic Advances in Gastroenterology, 2015-07, Vol.8 (4), p.189-205

2015

Volltextzugriff (PDF)

Relationship among DDR gene mutations, TMB and PD-L1 in solid tumour genomes identified using clinically actionable biomarker assays

NPJ precision oncology, 2023-10, Vol.7 (1), p.103-103, Article 103

2023

Volltextzugriff (PDF)

Comment on the FOWARC Study Report

Journal of clinical oncology, 2017-05, Vol.35 (13), p.1494-1494

Gounaris, Ioannis

2017

Volltextzugriff (PDF)

Ovarian clear cell carcinoma-bad endometriosis or bad endometrium?

The Journal of pathology, 2011-10, Vol.225 (2), p.157-160

2011

Volltextzugriff (PDF)

Application of ARID1A to murine formalin-fixed paraffin embedded tissue using immunohistochemistry [version 2; peer review: 2 approved]

F1000 research, 2014-01, Vol.3, p.244-244

2014

Volltextzugriff (PDF)

Application of ARID1A to murine formalin-fixed paraffin embedded tissue using immunohistochemistry

F1000 research, 2015-06, Vol.3, p.244

2015

Volltextzugriff (PDF)

Pulmomary embolism in Bradford, UK: role of end-tidal CO^sub 2^ as a screening tool

Clinical medicine (London, England), 2014-08, Vol.14 (4), p.455

Gounaris, Ioannis

2014

Volltextzugriff (PDF)

Pulmomary embolism in Bradford, UK: role of end-tidal CO2 as a screening tool

Clinical medicine (London, England), 2014-08, Vol.14 (4), p.455-455

Gounaris, Ioannis

2014

Volltextzugriff (PDF)

Practical implementation of the partial ordering continual reassessment method in a Phase I combination‐schedule dose‐finding trial

Statistics in medicine, 2022-12, Vol.41 (30), p.5789-5809

2022

Volltextzugriff (PDF)

Survival of patients with metastatic breast cancer with or without locoregional therapy

The lancet oncology, 2015-12, Vol.16 (16), p.e585-e585

Gounaris, Ioannis

2015

Volltextzugriff (PDF)

A phase I study of highly potent oral ATR inhibitor (ATRi) tuvusertib plus oral PARP inhibitor (PARPi) niraparib in patients with solid tumors

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.3018-3018

2024

Volltextzugriff (PDF)

A phase I study of ATR inhibitor gartisertib (M4344) as a single agent and in combination with carboplatin in patients with advanced solid tumours

British journal of cancer, 2024-04, Vol.130 (7), p.1131-1140

2024

Volltextzugriff (PDF)

First-in-Human Study of the Ataxia Telangiectasia and Rad3-Related (ATR) Inhibitor Tuvusertib (M1774) as Monotherapy in Patients with Solid Tumors

Clinical cancer research, 2024-05, Vol.30 (10), p.2057-2067

2024

Volltextzugriff (PDF)

Pharmacokinetic (PK) and pharmacodynamic (PD) findings from a phase 1b study of ATR inhibitor tuvusertib + anti-PD-L1 avelumab in patients with advanced unresectable solid tumors

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.2614-2614

2024

Volltextzugriff (PDF)

Pharmacodynamic (PD) and immunophenotyping analyses of ATR inhibitor (ATRi) tuvusertib + ATM inhibitor (ATMi) lartesertib in a phase Ib study in patients with advanced unresectable solid tumors

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.2612-2612

2024

Volltextzugriff (PDF)

Abstract 2312: Single-cell low pass whole genome sequencing for copy-number profiling in circulating tumor cells from prostate, non-small cell lung and breast cancers

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (7_Supplement), p.2312-2312

2023

Volltextzugriff (PDF)

Molecular pathogenesis of ovarian clear cell carcinoma

Future oncology (London, England), 2015-05, Vol.11 (9), p.1389-1405

2015

Volltextzugriff (PDF)

Neoadjuvant trials in early breast cancer: pathological response at surgery and correlation to longer term outcomes - what does it all mean?

BMC medicine, 2015-09, Vol.13 (1), p.234-234, Article 234

2015

Volltextzugriff (PDF)

A first-in-human phase I study of ATR inhibitor M1774 in patients with solid tumors

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.TPS3153-TPS3153

2021

Volltextzugriff (PDF)

1 – 25 von 143

Suche als RSS-Feed

Aktive Filter

ThemaComputer Science

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(78)
Mit Volltextzugriff
(128)

Publikationsform

Sprache

Englisch
(143)

Erscheinungsjahr

n.n

Thema

Science & Technology
(49)
Life Sciences & Biomedicine
(45)
Humans
(37)
Female
(28)
Oncology
(21)
Adult
(16)
Middle Aged
(15)
Aged
(14)
Breast Cancer
(13)
Chemotherapy
(10)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(9)
General & Internal Medicine
(9)
Medicine, General & Internal
(9)
Metastasis
(9)
Breast Neoplasms - Drug Therapy
(7)
Gene Expression
(7)
Ovarian Cancer
(7)
Health Aspects
(6)
Womens Health
(6)
Antineoplastic Agents - Therapeutic Use
(5)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer

Exploratory Analysis of TP53 Mutations in Circulating Tumour DNA as Biomarkers of Treatment Response for Patients with Relapsed High-Grade Serous Ovarian Carcinoma: A Retrospective Study

Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trial

Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 2×2 factorial randomised phase 3 trial

Ribociclib, a CDK 4/6 inhibitor, plus endocrine therapy in Asian women with advanced breast cancer

Docetaxel and its potential in the treatment of refractory esophagogastric adenocarcinoma

Relationship among DDR gene mutations, TMB and PD-L1 in solid tumour genomes identified using clinically actionable biomarker assays

Comment on the FOWARC Study Report

Ovarian clear cell carcinoma-bad endometriosis or bad endometrium?

Application of ARID1A to murine formalin-fixed paraffin embedded tissue using immunohistochemistry [version 2; peer review: 2 approved]

Application of ARID1A to murine formalin-fixed paraffin embedded tissue using immunohistochemistry

Pulmomary embolism in Bradford, UK: role of end-tidal CO^sub 2^ as a screening tool

Pulmomary embolism in Bradford, UK: role of end-tidal CO2 as a screening tool

Practical implementation of the partial ordering continual reassessment method in a Phase I combination‐schedule dose‐finding trial

Enhanced detection of circulating tumor DNA by fragment size analysis

Survival of patients with metastatic breast cancer with or without locoregional therapy

A phase I study of highly potent oral ATR inhibitor (ATRi) tuvusertib plus oral PARP inhibitor (PARPi) niraparib in patients with solid tumors

A phase I study of ATR inhibitor gartisertib (M4344) as a single agent and in combination with carboplatin in patients with advanced solid tumours

First-in-Human Study of the Ataxia Telangiectasia and Rad3-Related (ATR) Inhibitor Tuvusertib (M1774) as Monotherapy in Patients with Solid Tumors

Pharmacokinetic (PK) and pharmacodynamic (PD) findings from a phase 1b study of ATR inhibitor tuvusertib + anti-PD-L1 avelumab in patients with advanced unresectable solid tumors

Pharmacodynamic (PD) and immunophenotyping analyses of ATR inhibitor (ATRi) tuvusertib + ATM inhibitor (ATMi) lartesertib in a phase Ib study in patients with advanced unresectable solid tumors

Abstract 2312: Single-cell low pass whole genome sequencing for copy-number profiling in circulating tumor cells from prostate, non-small cell lung and breast cancers

Molecular pathogenesis of ovarian clear cell carcinoma

Neoadjuvant trials in early breast cancer: pathological response at surgery and correlation to longer term outcomes - what does it all mean?

A first-in-human phase I study of ATR inhibitor M1774 in patients with solid tumors

Aktive Filter

Suchergebnisse filtern